Trial Profile
A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Eflornithine (Primary) ; Lomustine
- Indications Anaplastic astrocytoma
- Focus Registrational; Therapeutic Use
- Acronyms STELLAR; STELLAR
- Sponsors Orbus Therapeutics
- 19 Jan 2022 Planned End Date changed from 1 Dec 2022 to 1 Jun 2023.
- 19 Jan 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2023.
- 12 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.